PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients
Status:
Completed
Trial end date:
2018-06-20
Target enrollment:
Participant gender:
Summary
The investigators propose to use autologous fecal microbiota transplantation (AFMT) to acute
myeloid leukemia (AML) patients treated with intensive chemotherapy and antibiotics in order
to restore the balance of their intestinal microbiome and thereby eradicate treatment-induced
multidrug resistant bacteria (MDRB), infection-related complications, as well as sequelae to
the gastrointestinal tract. Therefore, the investigators propose to perform a single-arm
multicentre prospective fecal microbiota transplantation (FMT) trial in AML patients
receiving intensive chemotherapy, and who are usually heavily treated with broad-spectrum
antibiotics during aplasia that generate a profound status of dysbiosis. For this purpose, at
the time of admission and AML diagnosis, patients will be requested to donate stools that
will be comprehensively screened, and if deemed appropriate according to protocol criteria,
conditioned and stored frozen until future processing and transplantation after aplasia
completion.